Are Elevated Plasma D-Dimer Levels a Reliable Marker of Disease Severity of Vaso-Occlusive Crisis in Sickle Cell Anaemia?
Main Article Content
Abstract
Background: Sickle Cell Anaemia (SCA) is characterized by a hypercoagulable state due to complex activation of haemostatic pathways involving red cell membrane changes, endothelial injury and cellular activation. Vaso-occlusive crisis (VOC), the most common acute complication in SCA, results from microvascular obstruction leading to tissue hypoxia and pain. This study determined plasma D-dimer levels during Bone Pain Crises (BPC), the steady state, and evaluated its utility as a marker of disease severity in SCA patients.
Materials and Methods: Forty-five adult SCA patients were recruited from a Nigerian teaching hospital during bone pain crises (BPC) and reassessed four weeks post-therapy in steady state. Clinical and laboratory parameters, including pain scores, haematological indices, and D-dimer levels were measured. Severity scores were calculated based on clinical complications and laboratory values.
Results: The study findings demonstrated significantly elevated median D-dimer levels during BPC (3.2 µg/ml) compared to the steady state (1.8 µg/ml, p = 0.004), consistent with increased fibrinolytic activity during acute crises. Haematocrit decreased (p = 0.002), white cell counts increased (p < 0.0001), and platelet counts decreased (p = 0.005) during VOC, reflecting an acute inflammation response. Males exhibited higher D-dimer levels than females during VOC (6.3 vs. 3.6 µg/ml, p = 0.002). Weak correlations were observed between D-dimer levels and disease severity indices, with no significant correlation overall (ρ = 0.217, p = 0.152).
Conclusion: This study confirms that BPC in SCA is associated with a hypercoagulable state and increased fibrinolytic activity, as evidenced by elevated D-dimer levels. However, D-dimer may not reliably reflect disease severity during BPC. The findings support the potential role of D-dimer as a biomarker of coagulation activation during VOC and underscore the importance of considering anticoagulant therapies in managing acute SCA complications.
Downloads
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
1. Ataga, K. Hypercoagulability and thrombotic complications in hemolyticanemias. Haematologica 94, 1481-4 (2009).
2. Ataga, K. & Key, N. Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am. Soc. Hematol. Educ. Program 2, 91-6 (2007).
3. Okpala, I. in Synopsis of Haematology including blood diseases in the tropics (eds. Okpalla, I. & Johnson, C.) 47-59 (CreateSpace, 2010).
4. Adekile, A. in Paediatrics and Child Health in a Tropical Region (eds. Azubuike, J. & Nkanginieme, K.) 194-213 (African Educational Services, 1991).
5. Rosse, W., Narla, M., Petz, L. & Steinberg, M. New Views of Sickle Cell Disease Pathophysiology and Treatment. Hematol. -the Educ. Progr. Am. Soc. Hematol. Hematology, 2-17 (2000).
6. Serjeant, G. & Serjeant, B. in Sickle Cell Disease 281-300 (Oxford University Press, 2001).
7. Ballas, S. More definitions in sickle cell disease?: Steady state v base line data. Am. J. Hematol. 2009 (2010). doi:10.1002/ajh.22259
8. Lijnen, H. & Collen, D. in Hoffman: Haematology Basic Principles and Practice (eds. Hoffman, R. et al.) 1805-1815 (Churchill Livingstone, 2000).
9. Robert, H., Monroe, D. & Hoffman, M. in Williams Hematology (eds. Beutler, E., Litchman, M., Coller, B., Kipps, T. & Seligsohn, U.) 145-117 (McGraw Hill, 2000).
10. Cook, C. et al. The clinical and laboratory spectrum of Hb C [?6(A3)Glu?Lys, GAG>AAG] disease. Hemoglobin 37, 16-25 (2013).
11. Okocha, E. C. et al. Serum Ferritin and Severity Scores in Sickle Cell Disease Patients in Nnewi ( South East Nigeria ). Br. J. Med. Med. Res. 11, 1-7 (2016).
12. Hedo, C., Akenova, Y., Okpala, I., Durojaiye, A. & Salimonu, L. Acute phase reactants and severity of homozygous sickle cell disease. J. Intern. Med. 233, 467-470 (1993).
13.Kabrhel C, et al. Factors associated with positive D- dimer results in patients evaluated for pulmonary embolism. Acad Emerg Med. 2010;17(6):589-97.
14. Francis RB Jr. Elevated fibrin D-dimer fragment in sickle cell anemia: evidence for activation of coagulation during the steady state as well as in painful crisis. Am J Hematol. 1989;31(4):265-9.
15. Ibrahim SA, Mukhtar IG, Mohammed AB, Mohammed KA, Yusuf T. Elevated Plasma D- Dimer Levels in Children with Sickle Cell Anemia in Steady State Attending State Specialist Hospital Maiduguri, Borno State, Nigeria. Niger J Med 2020; 29(4): 634-637.
16. Adebola, M. B., Olanrewaju, D. M., Ogundeyi, M. M., & Shonde-Adebola, K. B. (2018). Coagulation Changes in Children with Sickle Cell Anaemia during Painful Crises and Steady State at Federal Medical Centre Abeokuta, Nigeria. Nigerian Journal of Paediatrics 2018; 5(12), 1-17.
17. Ataga KI, Cappellini MD, Rachmilewitz EA. Beta- thalassemia and sickle cell anemia as paradigms of hypercoagulability. Hematology. 2007;139(1):91-6.
18. Nolan VG, Zhang Y, Saw NB, et al. WBC count is associated with hospital admissions for pain in children with sickle cell disease. Blood. 2008;112(3):1115-7.
19. Krishnan S, et al. Increased levels of microparticles in sickle cell disease: pathophysiology and significance. Blood Cells Mol Dis. 2008;41(1):104-12.
20. Fakunle EE, Eteng KI, Shokunbi WA. D-D dimer levels in patients with sickle cell disease during bone pain crises (BPCs) and in the steady state. Pathology & Laboratory Medicine International, 2012;4:21-25